| Literature DB >> 31387468 |
Tsai-Ju Chien1,2, Chia-Yu Liu2,3,4,5, Ching-Ju Fang6,7.
Abstract
Background: Breast cancer-related lymphedema (BCRL) is hard to control. Management may include lymphatic drainage, skin care, bandaging, or even surgery. Since acupuncture has been proven to affect the neurophysiology and neuroendocrine systems, it has the potential to control BCRL. Aim: To evaluate the effect of acupuncture in BCRL in randomized controlled trials. Design: A literature search was performed, following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement and without language restrictions. Data Sources: Five databases were searched from inception tthrough September 2018. Only studies that fulfilled the eligibility criteria of evaluating the effect of acupuncture on lymphedema in breast cancer were included. The methodological quality of these trials was assessed using the Cochrane criteria, and meta-analysis software (RevMan 5.3) was used for analysis.Entities:
Keywords: acupuncture; breast cancer–related lymphedema; controlled clinical trials; randomized; systematic review
Mesh:
Year: 2019 PMID: 31387468 PMCID: PMC6686319 DOI: 10.1177/1534735419866910
Source DB: PubMed Journal: Integr Cancer Ther ISSN: 1534-7354 Impact factor: 3.279
Figure 1.Studies selection flowchart, which is based on PRISMA statement.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.
The Comparisons of the Characteristics of the Included Trials.
| Author (Year)/Trial Type | Sample Size/Control | Inclusion Criteria/Status About Lymphedema | Intervention (Primary Acupoints) | Course | Measurement Tools | Results |
|---|---|---|---|---|---|---|
| Bao et al[ | 73/wait-list | 1. Affected arm circumference >2 cm larger than the
unaffected arm in at least 1 of the 2 sites | CV12 and CV3, and at bilateral TE14, LI15, LU5, LI4, ST36, and SP6 points | Twice weekly manual acupuncture for 6 weeks | Circumference and bioimpedance | 1. Compared lymphedematous arm versus unaffected
arm |
| Yao et al[ | 30/diosmin 900 mg 3 times daily | 1. ≥3 cm circumference differences between the affected and
unaffected arms | 30 minutes of acupuncture at 6 acupoints (Shousanli [LI.10], Quchi [LI.11], Binao [LI.14], Jianyu [LI.15], Waiguan [SJ.5], and Jianliao [SJ.14]) | Three times per week for 30 days | Arm circumference, QoL, clinical safety, and adverse events | 1. Compared lymphedematous arm versus unaffected
arm |
| Jeong et al[ | 9/nil | 1. ≥2 cm difference in a circumferential measurement of the
affected upper limb in comparison with the contralateral
limb | Saam acupuncture; the 5 Shu points | 3 times per week for 6 weeks | Stages of lymphedema, VAS, arm circumference, and QoL | 1. Compared lymphedematous arm versus the unaffected
arm |
| Smith et al[ | 20/treatment as usual | 1. ≥10 cm segment by bioimpedance | CV12, CV3, CV2; LI15, TE4, LU5, LI4, ST36, SP9, and SP6 | Twice weekly for 4 weeks then once weekly for 4 weeks; 8weeks | Extracellular fluid, lymphedema symptoms, well-being, and safety | 1. Compared pre- versus posttreatment |
| Cassileth et al[ | 37/nil | 1. ≥2 cm arm circumference differences between affected and
unaffected arms | TE14, LI15, LU5, CV12, CV3, LI4, ST36, and SP6 | Twice weekly for 4 weeks | Arm circumference at 2 points | 1. Two-point circumference measurements of the affected and
unaffected arms were performed before and after each
treatment session |
| Cassileth et al[ | 9/nil | 1. ≥2 cm arm circumference differences between the affected
and unaffected limbs | LI15, LI4, TE14, CV12, CV3, LU5, SP6, and ST36 | Twice a week for 4 weeks | Arm circumference (response was defined as at least a 30% reduction in the difference in size between the affected and unaffected arms after 4 weeks of treatment) | 1. Compared both the affected and unaffected limbs, before
and after each treatment |
Abbreviations: RCT, randomized controlled trial; QoL, quality of life; BCRL, breast cancer–related chronic lymphedema; VAS, Visual Analogue Scale; CI, confidence interval.
Figure 2.The summary of risk od bias of the included trials.
Risk of Bias in the Included Trials[a].
| Author (Year) | Randomization | Allocation Concealment | Patients Blinding | Assessor Blinding | Incomplete Outcome Data Addressed | Selective Outcome Reporting | Modified Jaded Scale |
|---|---|---|---|---|---|---|---|
| Bao et al[ | Low | Low | Low | Low | Low | Low | 5 |
| Yao et al[ | Low | Low | Low | Low | Low | Low | 5 |
| Jeong et al[ | High | Unclear | High | Unclear | Low | Low | 2 |
| Smith et al[ | Low | Low | Low | Low | Low | Low | 5 |
| Cassileth et al[ | High | Unclear | Unclear | Unclear | Low | Low | 2 |
| Cassileth et al[ | High | Unclear | Unclear | Unclear | Low | Low | 2 |
Modified Jadad Scale: Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
Figure 3.Effect of acupuncture on extent of lymphedema in acupuncture in breast cancer–related lymphedema (arm circumference).